Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05376371
Other study ID # 2022-0398
Secondary ID 1R01DA047889-01A
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date November 29, 2022
Est. completion date June 2025

Study information

Verified date June 2024
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to enroll 220 incarcerated individuals living with HIV, Hepatitis C (HCV), or history of substance misuse preparing for release into a pilot implementation study to test the feasibility and acceptability of an adapted Coordinated Transitional Care intervention in a Criminal Justice setting (CJC-TraC). Participants can expect to be on study for up to 6 months.


Description:

This protocol describes the second, implementation phase of a 5-year NIH-funded research project designed to evaluate post-incarceration health care utilization and outcomes for underserved people living with HIV, HCV and substance use disorder. In the first study phase, conducted from 2020-21, the investigators analyzed Wisconsin Medicaid data to characterize the baseline level of outpatient care utilization for adults during their first 6 months after release from prison, and conducted formative research necessary to adapt an existing transitional care intervention, called C-TraC, to support individuals leaving prison. The current project aims to enroll participants in a pilot implementation study to test the feasibility and acceptability of the adapted intervention in a criminal justice setting, which has been given the name "CJC-TraC." Participants will be enrolled from one of two institutions: - men from Oakhill Correctional Institute (OCI) - women from the Wisconsin Women's Correctional System (WWCS) Primary Objectives: To evaluate the feasibility and acceptability of CJC-TraC when implemented in a state prison system. Secondary Objectives: To gather preliminary evidence describing the effectiveness of CJC-TraC for improving the rate of outpatient care utilization.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 220
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Able to understand and speak in English - Plans to reside in Wisconsin after release - Eligible for Wisconsin Medicaid and willing to enroll prior to release - Has a history of one or more of the following: current HIV infection, current or past HCV infection, identified need for substance use related services based on Correctional Offender Management Profiling for Alternative Sanctions (COMPAS) assessment - Anticipated release date (must be within 6 months of review) Exclusion Criteria: - Unable to provide informed consent form or impaired ability to make decisions - Planned discharge to another correctional facility or other carceral setting (e.g. release to jail or immigration detention center)

Study Design


Intervention

Other:
CJC-TraC
CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.

Locations

Country Name City State
United States Oakhill Correctional Institution Oregon Wisconsin
United States Robert E. Ellsworth Correctional Center Union Grove Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility Outcome: Number of participants who are enrolled and complete the baseline study assessment per month The investigators aim to enroll about 9 people per month over a 2 year study period. Results will be reported in total and per institution. at enrollment, up to 1 day
Primary Feasibility Outcome: Number of pre-release CJC-TraC intervention sessions completed with the nurse case manager for each participant The investigators plan for 3 pre-release sessions with additional sessions as needed. The results will be reported in total and for each institution. pre-release, up to 3 months
Primary Feasibility Outcome: Number of post-release telephone contacts between the CJC-TraC nurse case manager and study participants The investigators plan for 2 post-release sessions with additional sessions as needed. post-release, up to 6 months
Primary Feasibility Outcome: Proportion of study participants who are retained in follow-up for three months and complete the end-of-study assessment within 3-months following release (up to 6 months on study)
Primary Acceptability measured by the Proportion of study participants who rated specific aspects of the intervention useful and encounter volumes appropriate Of participants who enroll and complete a follow up assessment, percentage of participants who responded to questions soliciting their perspectives about the intervention usefulness within 3-months following release (up to 6 months on study)
Primary Acceptability assessed by subjective experience of the Participant (Qualitative Measure) Participant responses to qualitative interview questions will be analyzed for themes, responses to questions regarding helpful and liked parts of the intervention and work with the nurse case manager will be particularly meaningful for acceptability within 3-months following release (up to 6 months on study)
Primary Acceptability measured by the Proportion of Department of Corrections (DOC) staff who rated the intervention acceptable, useful, or appropriate up to 3 months
Secondary Number of non-emergency outpatient visits observed within 3-months following release within 3-months following release (up to 6 months on study)
Secondary Number days until the first non-emergency outpatient visit following release. within 3-months following release (up to 6 months on study)
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2